Abstract: The present invention relates to a novel melatonin-based formulation, particularly a topical liquid composition of melatonin (or analog thereof) suitable for use in intrauterine washing performed during medically assisted reproduction (e.g. in vitro fertilization—IVF). Melatonin is notoriously unstable, especially in solution. The compositions of the invention exhibit high stability, which allows them to be kept for prolonged periods before their eventual use in the inhibition or prevention of embryonic implantation failure.

Abstract: The present invention relates to a novel melatonin-based formulation, particularly a topical liquid composition of melatonin (or analog thereof) suitable for use in intrauterine washing performed during medically assisted reproduction (e.g. in vitro fertilisation—IVF). Melatonin is notoriously unstable, especially in solution. The compositions of the invention exhibit high stability, which allows them to be kept for prolonged periods before their eventual use in the inhibition or prevention of embryonic implantation failure.

Abstract: The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent.

Abstract: The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent.

Abstract: The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent.

Abstract: The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent.

Abstract: The invention relates to growth hormone (GH) formulations having sustained-release properties, in particular human growth hormone (hGH) and methods for their preparation. The growth hormone formulations can be manufactured without denaturing of the protein and can conveniently be administrated to the person in need thereof by using a conventional syringe via a needle having a small diameter.

Abstract: The invention relates to liquid pharmaceutical formulations of luteinizing hormone (LH) for single- or multi-dose administration.

Abstract: The invention relates to growth hormone (GH) formulations having sustained-release properties, in particular human growth hormone (hGH) and methods for their preparation. The growth hormone formulations can be manufactured without denaturing of the protein and can conveniently be administrated to the person in need thereof by using a conventional syringe via a needle having a small diameter.

Abstract: The invention relates to liquid pharmaceutical formulations of luteinizing hormone (LH) for single- or multi-dose administration.

Abstract: The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent.

Abstract: The invention relates to new macrocyclic phthalocyanine-like systems. In particular, object of the invention are new macrocyclic porphyrazine-type compounds and metal derivatives thereof, in which heterocycle rings are provided at the periphery of the inner porphyrazine fragment. A further object of the invention is a process for obtaining, as an example, tetra(thiadiazolo)porphyrazine, or tetra(selenediazolo)porphyrazine, by means of cyclotetramerization of the monomers 3,4-dicyano-1,25-thiadizole, or 3,4-dicyano-1,2,5-selenodiazole with metallorganico or inorganic salts, in organic solvents, extraction, if any, of the metal from the complexes thus formed by treatment with strong acids to obtain tetra(thiadiazolo)porphyrazine, or tetra(selenediazolo)porphyrazine, and by treatment, if any, of these compounds with a metallorganic or inorganic salt to obtain the metal derivatives thereof different from those previously extracted.